おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Abliva AB
company
About
Abliva develops medicines for the treatment of primary mitochondrial diseases.
- 1 - 10
Details
- Last Funding Type
- Grant
- Last Funding Money Raised
- $4.09M
- Industries
- Biotechnology,Clinical Trials,Health Care
- Founded date
- Jan 1, 2000
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare and often very severe diseases occur when the cell's energy provider, the mitochondria, do not function properly. The portfolio includes projects at different stages and ranges from early discovery phase to clinical phase.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$4.09M
Abliva AB has raised a total of
$4.09M
in funding over 2 rounds. Their latest funding was raised on
Aug 29, 2018 from a Grant round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 29, 2018 | Grant | $4.09M | 1 |
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
Abliva AB is funded by 1 investors.
Congressionally Directed Medical Research Programs
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Grant |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
